Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
Acquiring Company
Orgenesis Inc.
Acquired Company
Octomera
GermantownBiotechnologyPharmaceutical ManufacturingDescription
Orgenesis Inc. has entered into a definitive agreement to acquire the approximate 25% stake in Octomera LLC, thereby allowing Orgenesis to have 100% ownership of this core strategic business unit. The acquisition aligns with Orgenesis' goal of progressing its decentralized immuno-oncology portfolio to the clinic and reinforces its commitment to advancing cell and gene therapies towards commercialization.
Quick answer
Orgenesis Inc. is acquiring Octomera, announced January 31, 2024. Orgenesis Inc. is based in Germantown, Maryland, United States.
- How much did Orgenesis Inc. pay for Octomera?
- The deal value was not disclosed.
- What does Orgenesis Inc. do?
- Orgenesis Inc. is a global biotech company committed to unlocking the potential of cell and gene therapies (CGTs) and pioneering a decentralized approach to processing since 2020.
- Where are Orgenesis Inc. and Octomera based?
- Orgenesis Inc. is based in Germantown, Maryland, United States.
- Who are the decision-makers at Orgenesis Inc?
- Fundz holds 1 contact at Orgenesis Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical Manufacturing and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Merck Animal Health to Acquire Elanco’s Aqua Business (February 5, 2024)
- Astellas Completes Acquisition Of Propella Therapeutics (December 21, 2023)
- Novartis completes acquisition of IFM Due to develop first-in-class STING antagonist program targeting innate immune system (March 13, 2024)
- Ordaōs completes acquisition of the Carterra®LSA® Platform to optimize its machine-driven drug design system (March 11, 2024)
- Bruker Corporation completes acquisition of Chemspeed Technologies AG to expand vendor-agnostic scientific software and laboratory automation (March 7, 2024)
- Telix Pharmaceuticals Limited to acquire ARTMS Inc. and its Advanced Isotope Production Platform (March 4, 2024)
Who to call at Orgenesis Inc., and when
When Orgenesis Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Orgenesis Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Orgenesis Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Orgenesis Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Orgenesis Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Octomera?
Octomera was acquired by Orgenesis Inc., based in Germantown. The deal was reported on January 31, 2024. Orgenesis Inc. is a global biotech company committed to unlocking the potential of cell and gene therapies (CGTs) and pioneering a decentralized approach to processing since 2020. Orgenesis Inc. is privately held and operates in Biotechnology.
When did Orgenesis Inc. acquire Octomera?
Orgenesis Inc.'s acquisition of Octomera was reported on January 31, 2024. Orgenesis Inc. has entered into a definitive agreement to acquire the approximate 25% stake in Octomera LLC, thereby allowing Orgenesis to have 100% ownership of this core strategic business unit. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Octomera do?
Octomera LLC is the cell processing services subsidiary of Orgenesis Inc., focused on advancing decentralized GMP production and proprietary therapeutics. It is privately held, operating in Pharmaceutical Manufacturing.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.